| 摘要 |
Disclosed is a sulphonic acid of formula (I): A-B-SO3H wherein: A represents a group selected from OH, NH2, SO3H and CO2H; B represents an arylene group or a linear or branched C1-C12alkylene chain optionally substituted by one or more groups selected from hydroxy, oxo, amino, SO3H and CO2H and in which one or more carbon atoms is optionally replaced by an oxygen atom, by a nitrogen atom or by an SO2 group, with the exclusion of strontium bis(aminomethanesulphonate), strontium methane disulphonate, strontium 1,3-benzenedisulphonate, strontium 6-suiphonatohexanoate, strontium 1,5-naphthalenedisulphonate, strontium 1,6-naphthalenedisulphonate, strontium bis(6-hydroxy-2-naphthalenesulphonate), strontium 2-oxo-1,3-propane- disulphonate, strontium hydroxymethanesulphonate, strontium bis(4-aminobenzene-sulphonate), strontium bis(2- aminobenzene-sulphonate), strontium bis(3-aminobenzene-sulphonate), strontium 1,2-ethanedisulphonate and strontium 3-amino-3-carboxy-1-propanesulphonate chloride, and wherein: arylene being understood to be phenylene, biphenylylene or naphthylene, each of those groups being optionally substituted by one or more identical or different groups selected from linear or branched C1-C12alkylene, OH, NH2, SO3H and CO2H. Also disclosed is a process for the preparation of a strontium salt by reaction of a sulphonic acid of formula (I) with strontium hydroxide, followed by isolation of the strontium salt so obtained; and alternatively by reaction of the sodium or potassium salt of a sulphonic acid of formula (I): with strontium chloride, followed by isolation of the strontium salt so obtained. These strontium salts are suitable in the manufacture of medicaments for use in the prevention or treatment of osteoarthritis and osteoporosis.
|
